The synergistic effect of propofol and ulinastatin suppressed the viability of the human lung adenocarcinoma epithelial A549 cell line

Li, Ping; Guo, Peipei; Chen, Lin; He, Murong; Zhu, Xiaojuan; Liu, Chuan; Tang, Jing; Wang, Wei; Li, Weidong

doi:10.3892/ol.2018.9283

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, absorbance was measured at a wavelength of 450 nm using a microplate reader. Viability was determined as follows: viability (%) = [1 - (At-Ab)/(Ac-Ab)] × 100 [ 12 ] , where At, Ab and Ac represent absorbance values of treatment, blank and control, respectively. The experiments were performed in triplicate.…”

Section: Methodsmentioning

confidence: 99%

Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

Yan¹,

Xie²,

Dai³

et al. 2021

CDR

View full text Add to dashboard Cite

Aim: Liver cancer is one of the most common malignancies and has a high recurrence rate. However, current treatment strategies do not achieve satisfactory outcomes in the clinic. To explore a new strategy to enhance the effectiveness of chemotherapy in liver cancer, we investigated whether dichloroacetate (DCA) could enhance the sensitivity of liver cancer cells to pirarubicin (THP).Methods: Liver cancer cells were treated with DCA alone, THP alone, or DCA and THP combined. Cell viability was determined by the CCK-8 assay. Cell apoptosis was analyzed by flow cytometer. Reactive oxygen species (ROS) were detected using a CM-H2DCFDA fluorescence probe. Protein levels were identified by immunoblotting. Results:The results revealed that DCA significantly enhanced the antitumor effect of THP in liver cancer cells. Changes in morphology and adherence ability were observed, as well as decreased cell viability. The results of flow cytometry showed that the combination of THP and DCA significantly increased apoptosis of liver cancer cells. Moreover, compared with THP alone, combination treatment with DCA significantly increased THP-triggered ROS generation in liver cancer cells. The antioxidant N-acetyl-L-cysteine reversed the synergistic effect of DCA and THP on ROS generation, cell viability and apoptosis. Furthermore, phosphorylation of c-Jun N-terminal kinase

show abstract

Section: Methodsmentioning

confidence: 99%

Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

Yan¹,

Xie²,

Dai³

et al. 2021

CDR

View full text Add to dashboard Cite

show abstract

“…Approximately 57% of lung AD have advanced to metastatic diseases, and the prognosis of patients is adversely affected by organ metastasis. [10][11][12] Lung, bone, brain, pleura and liver are the common metastatic organs of LUAD. [9] New predictive tools and devices are urgently needed in clinical practice for better prognosis of lung AD.…”

Section: Introductionmentioning

confidence: 99%

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

The effect of various metastases patterns on the prognosis of lung adenocarcinoma (AD) remains unknown. The purpose of our retrospective study is to determine whether various metastases patterns have a prognostic impact on patients with organ metastatic lung AD. Patient data was extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan–Meier method was chosen for the evaluation of overall survival (OS) rate. Univariable and multivariable Cox regression analyses were conducted to evaluate independent prognostic factors. In the SEER database, 12,228 patients with IV lung AD were retrieved in total. And 78.78% of those patients (9633/12,228) suffered from one of brain, lung, liver or bone metastasis due to disease progression. It was found that the most common site in patients with metastatic lung AD was brain (21.20%), and the least common site of metastasis was liver (3.50%). Patients who suffered single lung metastatic showed relatively good OS, and the median survival time was 11 months (95% CI 0.470–0.516). For those with 2 metastatic sites, data analysis suggested that the median survival times of patients with bone and lung metastasis (10 months; 95% CI 0.469–0.542) were better than others. For those with 3 metastatic sites, data analysis suggested that metastatic pattern had no effect on the OS. Brain is the most common single metastasis site of lung AD. Compared with the other 3 metastatic sites, patients with lung metastasis had better survival results. Deeper knowledge of metastatic patterns will help doctors to better understand the prognosis and formulate more appropriate treatment plans.

show abstract

“…Li et al [24] studies have shown that ulinastatin and protocol synergistically inhibit the proliferation and migration of human lung adenocarcinoma cells A549 and promote cell apoptosis. The results of this study showed that sevoflurane and ulinastatin had a synergistic effect on proliferation inhibition of H1975 cells, and the proliferation and migration of H1975 were significantly higher than that of sevoflurane and ulinastatin alone, suggesting that the administration of sevoflurane and ulinastatin during surgery for lung adenocarcinoma.…”

Section: Resultsmentioning

confidence: 99%

Effect of Sevoflurane Combined with Ulinastatin on Cell Proliferation and Migration in Lung Adenocarcinoma

Zhao,

Zhang,

Wang

et al. 2023

IJPS

View full text Add to dashboard Cite

To investigate the effect of sevoflurane combined with ulinastatin on cell proliferation and migration of human lung adenocarcinoma. Human lung adenocarcinoma cells H1975 were cultured in vitro, and treated with different concentrations of sevoflurane, ulinastatin and sevoflurane+ulinastatin, the cells were divided into control group, sevoflurane, ulinastatin and sevoflurane+ulinastatin group by cell counting kit 8; H1975 cell cycle by flow cytometry; the number of H1975 cells was measured by Transwell; protein immunoblot (Western blot). Compared with the control group, different concentrations of sevoflurane and ulinastatin treatment significantly inhibited the proliferation of H1975 cells in a dose-dependent manner. Sevoflurane combined with ulinastatin had a synergistic effect on cell proliferation inhibition in H1975 cells. Compared with the control group, the inhibition of cell proliferation and the proportion of cells in growth 0/growth 1 phase were significantly increased in the sevoflurane and ulinastatin groups, the proportion of cells in S phase, the number of cell migration, proliferation proteins cyclin D1, cyclin-dependent kinase 4, migration protein matrix metalloproteinase-2 and matrix metalloproteinase-9 were significantly decreased (p<0.05); compared with the sevoflurane group and the ulinastatin group, the inhibition of cell proliferation and the percentage of cells in growth 0/growth 1 group, the proportion of cells in S phase, cell migration number, proliferation proteins cyclin D1, cyclin-dependent kinase 4, migration proteins matrix metalloproteinase-2 and matrix metalloproteinase-9 were significantly decreased (p<0.05). Sevoflurane combined with ulinastatin can synergistically downregulate proliferation and migration protein expression and then inhibit the proliferation and migration of lung adenocarcinoma cells H1975, which may be a potential treatment for lung adenocarcinoma in clinical practice.

show abstract

The synergistic effect of propofol and ulinastatin suppressed the viability of the human lung adenocarcinoma epithelial A549 cell line

Cited by 5 publications

References 32 publications

Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma

Effect of Sevoflurane Combined with Ulinastatin on Cell Proliferation and Migration in Lung Adenocarcinoma

Contact Info

Product

Resources

About